JPMorgan Chase & Co. reiterated their overweight rating on shares of AstraZeneca (LON:AZN – Get Rating) in a research report report published on Wednesday, MarketBeat reports. The brokerage currently has a £120 ($151.00) price target on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a buy rating and set a £115 ($144.71) target price on shares of AstraZeneca in a research report on Thursday, May 19th. Morgan Stanley reaffirmed an overweight rating on shares of AstraZeneca in a research report on Wednesday, May 11th. Barclays reissued an overweight rating and issued a £120 ($151.00) price objective on shares of AstraZeneca in a report on Monday, May 9th. UBS Group set a £105 ($132.13) price objective on AstraZeneca in a report on Monday, March 7th. Finally, The Goldman Sachs Group set a GBX 6,950 ($87.45) price objective on AstraZeneca in a report on Friday, April 29th. One investment analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of Buy and a consensus target price of £104.75 ($131.81).
Shares of LON:AZN opened at £105.80 ($133.13) on Wednesday. The business’s 50-day moving average is £103.45 and its 200 day moving average is GBX 9,251.72. AstraZeneca has a 1 year low of GBX 7,870 ($99.03) and a 1 year high of £110 ($138.42). The firm has a market capitalization of £163.93 billion and a P/E ratio of -183.68. The company has a debt-to-equity ratio of 90.06, a current ratio of 1.00 and a quick ratio of 0.65.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.